Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Public ClinicalTrials.gov record NCT04374630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore, the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful step forward in the clinical management of these difficult-to-treat patients with PROC.
Study identification
- NCT ID
- NCT04374630
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2020 (Actual)
- Primary completion
- Oct 31, 2023 (Actual)
- Completion
- Jun 28, 2024 (Actual)
- Last update posted
- Oct 19, 2026
2020 – 2024
United States locations
- U.S. sites
- 30
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Phoenix | Arizona | 85016 | — |
| Arizona Oncology | Tucson | Arizona | 85711 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Gynecology Oncology Associates Newport Beach | Newport Beach | California | 92663 | — |
| Rocky Mountain Cancer Centers | Littleton | Colorado | 80120 | — |
| Kapiolani Medical Center for Women and Children | Honolulu | Hawaii | 96826 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Women's Cancer Care | Covington | Louisiana | 70433 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| University of Massachusetts | Worcester | Massachusetts | 01605 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| MD Anderson Cancer Center at Cooper | Camden | New Jersey | 08103 | — |
| Holy Name Medical Center | Teaneck | New Jersey | 07666 | — |
| Southwest Women's Oncology Group | Albuquerque | New Mexico | 87106 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| OHCare Oncology Hematology Care (OHC), Inc. - Kenwood Office | Cincinnati | Ohio | 45242 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Abington Memorial Hospital | Willow Grove | Pennsylvania | 19090 | — |
| Women & Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | — |
| Texas Oncology | Austin | Texas | 78731 | — |
| Texas Oncology | Fort Worth | Texas | 76104 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
| USO Texas Oncology | Longview | Texas | 75601 | — |
| US Texas Oncology | San Antonio | Texas | 78240 | — |
| Baylor Scott & White Medical Center | Temple | Texas | 76508 | — |
| Texas Oncology | The Woodlands | Texas | 77380 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| University of Washington/Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04374630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04374630 live on ClinicalTrials.gov.